Kathryn Das, DO
Cardiovascular Disease · Lansing, MINPI 1750760542
Payments from drug & device makers
Across 306 payments — averaging $42.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$3K
- Edwards Lifesciences$2K
- Boston Scientific$1K
- Novartis$969
- Amgen$654
- AstraZeneca$653
- plus $4K from 28 others
What the payments were for
- Grants$2,10016%
- Travel & lodging$2,07616%
- Food & beverage$8,84368%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 17 | $3,476 |
| Edwards Lifesciences | 10 | $1,855 |
| Boston Scientific | 37 | $1,345 |
| Novartis | 47 | $969 |
| Amgen | 24 | $654 |
| AstraZeneca | 13 | $653 |
| Johnson & Johnson | 31 | $572 |
| E.r. Squibb & Sons, L.L.C. | 23 | $504 |
| Abiomed | 5 | $368 |
| Boehringer Ingelheim | 12 | $321 |
| Medtronic | 7 | $278 |
| Actelion Pharmaceuticals US, Inc. | 9 | $258 |
| Pfizer | 13 | $238 |
| Shockwave Medical, Inc | 2 | $238 |
| Bayer | 14 | $230 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 12 | $203 |
| Sanofi-aventis U.S. LLC | 3 | $126 |
| Scpharmaceuticals Inc. | 2 | $117 |
| Kiniksa Pharmaceuticals International, PLC | 5 | $114 |
| Atricure, Inc. | 2 | $92 |
| Philips North America LLC | 1 | $74 |
| Alnylam Pharmaceuticals Inc. | 2 | $60 |
| Melinta Therapeutics, LLC | 3 | $49 |
| Merck | 2 | $28 |
| Cardiva Medical, Inc. | 1 | $24 |
| Lundbeck LLC | 1 | $23 |
| Bridgebio Pharma, Inc. | 1 | $22 |
| Novo Nordisk | 1 | $22 |
| Lexicon Pharmaceuticals, Inc. | 1 | $21 |
| Impulse Dynamics (USA) Inc. | 1 | $20 |
| Siemens Medical Solutions USA, Inc. | 1 | $19 |
| Inari Medical, Inc. | 1 | $18 |
| Livanova USA, Inc. | 1 | $15 |
| Sensible Medical Innovations Inc | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MitraClip$886
- EVOQUE$484
- FARXIGA$384
- Repatha$318
- ENTRESTO$247
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$238
- Impella$231
- BRILINTA$153
- PASCAL$145
- CAMZYOS$114
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$109
- XARELTO$105
- Watchman$102
- Confirm Rx$100
How this compares
$13,019 in reported general payments places this provider in the 70th percentile of 760 cardiovascular disease providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 123 | $189,018 |
| EntrestoSacubitril/Valsartan | 62 | $96,063 |
| FarxigaDapagliflozin Propanediol | 70 | $91,189 |
| XareltoRivaroxaban | 50 | $60,101 |
| JardianceEmpagliflozin | 43 | $56,360 |
| Repatha SureclickEvolocumab | 70 | $39,770 |
| Praluent PenAlirocumab | 12 | $9,537 |
| Rosuvastatin Calcium | 305 | $7,786 |
| Metoprolol Succinate | 199 | $3,770 |
| Ezetimibe | 96 | $3,293 |
| Losartan Potassium | 127 | $2,125 |
| ClopidogrelClopidogrel Bisulfate | 74 | $2,052 |
| Carvedilol | 130 | $1,981 |
| Amiodarone Hcl | 45 | $1,865 |
| Bumetanide | 38 | $1,772 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $238 | $189,018123 claims |
| NovartisEntresto | $969 | $96,06362 claims |
| AstraZenecaFarxiga | $653 | $91,18970 claims |
| Johnson & JohnsonXarelto | $572 | $60,10150 claims |
| Boehringer IngelheimJardiance | $321 | $56,36043 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 760 cardiovascular disease providers in Michigan.
Other cardiovascular disease in Lansing
- David StroblLansing$946K
- Chad LinkLansing$499K
- Ali SheikhLansing$205K
- Stanley ChetcutiAnn Arbor$4.3M
- Sandeep KhuranaGrandville$2.3M
- Victor MolesAnn Arbor$2.1M
- Jihad MustaphaGrand Rapids$1.9M
- Marschall RungeAnn Arbor$1.8M
- Sara SaberiAnn Arbor$1.6M
- Brian OneillDetroit$1.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.